NCT00250354View on ClinicalTrials.gov

A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation

PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

September 30, 1997

Study Completion Date

August 31, 1999

Conditions
Conduct DisorderOppositional Defiant DisorderDisruptive Behavior Disorder
Interventions
DRUG

Risperidone oral solution

All Listed Sponsors
lead

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

NCT00250354 - A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation | Biotech Hunter | Biotech Hunter